Welcome to our dedicated page for Mediwound SEC filings (Ticker: MDWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MediWound Ltd. SEC filings document a foreign private issuer focused on enzymatic therapeutics for tissue repair. Its Form 20-F annual reports and Form 6-K current reports cover operating and financial results, clinical and regulatory disclosures for NexoBrid and EscharEx, material-event updates, and registration-statement information tied to Form S-8 and Form F-3 filings.
The company’s filings also record governance and capital-structure matters, including annual and extraordinary shareholder meeting materials, proxy statements, board elections, ordinary share voting mechanics, and share incentive plan approvals under Israeli corporate governance requirements. Other disclosures address distribution and procurement-related developments for NexoBrid, risk factors, material agreements, and shareholder voting results.
MediWound Ltd.’s Chief Medical Officer, Ety Klinger, filed an initial Form 3 showing equity holdings in ordinary shares, stock options, and restricted share units. The filing lists multiple option grants to buy ordinary shares, including 3,571 underlying shares at an exercise price of 36.0500 that expire on December 31, 2028, and 5,491 underlying shares at 12.2500 that expire on April 23, 2030, along with several later-dated grants through March 4, 2036.
Footnotes describe RSU awards granted on February 15, 2023, February 26, 2024, February 11, 2025, and March 4, 2026, each vesting 25% on the first anniversary of grant and 6.25% quarterly over the following three years. The filing also records direct holdings of ordinary shares in several line items.
MediWound Ltd. director David Morton Fox filed an initial statement of beneficial ownership, outlining his equity stake in the company. He directly holds ordinary shares and additional ordinary shares underlying restricted stock units that were granted on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.
Fox also reports a series of equity incentives. These include Series A warrants$13.4750 per share, expiring on November 28, 2026. He holds multiple stock option grants, such as options over 14,285 ordinary shares at $12.2500 per share expiring on June 29, 2030, and other tranches with exercise prices between $11.8850 and $37.5200 expiring from 2031 through 2036. This filing records existing holdings and does not show new market transactions.
MediWound Ltd. VP Clinical & Reg. Affairs Aya Ben Yaakov filed an initial Form 3 reporting existing equity holdings in the company. The filing lists several stock options to buy ordinary shares at exercise prices between 12.25 and 37.52 with expirations from 2028 to 2036, plus ordinary shares, including amounts underlying RSUs. Footnotes explain that these RSUs and options vest over four years, with 25% vesting after one year and 6.25% vesting quarterly thereafter. The filing shows holdings only, without any reported purchases or sales.
MediWound Ltd. executive Meyer Yaron, EVP, General Counsel and Corporate Secretary, filed an initial Form 3 reporting his beneficial ownership in ordinary shares and stock options of MDWD.
The filing lists several stock option grants to buy ordinary shares, including options over 2,857 underlying shares at an exercise price of 36.0500 expiring on December 31, 2028, and 4,919 underlying shares at 12.2500 expiring on April 23, 2030. Additional grants cover 2,769 underlying shares at 37.5200 expiring on March 4, 2031, 9,230 underlying shares at 14.4200 expiring on May 16, 2032, and further awards expiring through 2036.
Yaron also reports direct holdings of ordinary shares tied to restricted stock units (RSUs). Footnotes explain RSU and option grants made on February 15, 2023, February 26, 2024, February 11, 2025, and March 4, 2026, each vesting 25% on the one-year anniversary of grant and 6.25% quarterly thereafter until fully vested after four years.
MediWound Ltd. filed an initial ownership report for director Stephen T. Wills, detailing his existing holdings in ordinary shares and stock options. The filing lists multiple stock option awards on ordinary shares with exercise prices ranging from 11.8850 to 37.5200 and expiration dates between 2029 and 2036. It also notes ordinary shares underlying RSUs and an option grant made on March 4, 2026 that vest 100% on the one-year anniversary of the grant date, showing his current equity-based alignment with the company.
MediWound Ltd. director Samuel Rubinstein filed an initial Form 3 reporting his equity holdings in the company. He holds stock options over 7,200, 7,542, 5,600 and 6,250 ordinary shares at exercise prices of $9.6400, $12.7290, $18.5400 and $17.6000, expiring between 2033 and 2036. He also holds 2,843 and 750 ordinary shares directly, plus 525 ordinary shares held indirectly by his spouse. Footnotes state that certain ordinary shares are underlying RSUs granted on March 4, 2026, and certain options were also granted on that date, with each grant vesting 100% on the one-year anniversary of the grant date.
MediWound Ltd. executive Hess Shmuel, the company’s COO and Chief Commercial Officer, reported his existing equity stake in a Form 3 insider filing. The filing lists stock options to acquire 32,000, 32,681, 24,000 and 31,000 ordinary shares at exercise prices of $8.1292, $12.7290, $18.5400 and $17.6000, expiring between December 1, 2033 and March 4, 2036.
He also reports direct holdings of 4,085, 3,000 and 3,800 ordinary shares, which footnotes explain are tied to restricted share units granted in 2024, 2025 and 2026, each vesting over four years. The Form 3 establishes his current ownership position and does not show any recent share purchases or sales.
MediWound Ltd. Chief Executive Officer Gonen Ofer filed an initial ownership report detailing his equity and derivative holdings in the company. The filing lists direct holdings of ordinary shares and multiple grants of restricted share units (RSUs) and stock options that vest over four-year schedules.
The report shows Series A Warrants exercisable into 8,168 ordinary shares at an exercise price of 13.4750 per share, expiring on November 28, 2026. It also outlines several stock option grants over different years, with exercise prices ranging from 11.8850 to 18.5400 per share and expirations from 2032 through 2036. Footnotes explain that both RSUs and options vest 25% after one year from grant and 6.25% each quarter over the next three years, providing long-term, performance-linked compensation rather than immediate open-market transactions.
MediWound Ltd. director Nachum Shamir has filed a Form 3 showing his initial ownership in the company. He directly holds 49,815 ordinary shares and an additional 1,200 ordinary shares underlying restricted stock units granted on March 4, 2026, which vest in full one year after the grant date.
He also holds a series of equity derivatives over MediWound ordinary shares. These include Series A warrants over 16,336 shares at an exercise price of 13.4750 per share expiring on November 28, 2026, and several stock option grants covering 28,571, 11,800, 12,570, 9,200 and 10,000 underlying shares with exercise prices between 11.8850 and 18.5400, expiring between August 17, 2032 and March 4, 2036. The options granted on March 4, 2026 vest 100% on the one-year anniversary of the grant date.
MediWound Ltd. files its 2025 annual report on Form 20-F, detailing its burn- and wound-care business, risk profile and financial position. The company reports a net loss of $23.9 million for 2025 and an accumulated deficit of $228.9 million as of year-end.
As of December 31, 2025, MediWound had 12,835,148 ordinary shares outstanding. The filing highlights reliance on NexoBrid sales, partner Vericel in North America, government contracts for temperature-stable NexoBrid, and a new GMP facility in Yavne, Israel that reached full manufacturing capacity in 2025.
MediWound Ltd. files its 2025 annual report on Form 20-F, detailing its burn- and wound-care business, risk profile and financial position. The company reports a net loss of $23.9 million for 2025 and an accumulated deficit of $228.9 million as of year-end.
As of December 31, 2025, MediWound had 12,835,148 ordinary shares outstanding. The filing highlights reliance on NexoBrid sales, partner Vericel in North America, government contracts for temperature-stable NexoBrid, and a new GMP facility in Yavne, Israel that reached full manufacturing capacity in 2025.